My Companies
Notification
Account
An unannounced US FDA inspection of Caplin Steriles’ Gummidipoondi injectable and ophthalmic facility concluded with 10 Form 483 observations. The company characterized them as procedural, with no data-integrity or repeat findings, and will respond within the stipulated timeframe.
Caplin Point Receives US FDA OAI Classification For Gummidipoondi Facility
Caplin Point Gains INVIMA GMP Compliance Confirmation For Oncology Manufacturing Unit